FCCC LOGO Faculty Publications
Segal DM , Weiner GJ , Weiner LM
Bispecific antibodies in cancer therapy
Current Opinion in Immunology. 1999 Oct;11(5) :558-562
PMID: ISI:000082862400014   
Back to previous list
Abstract
Based upon in vitro and animal studies, a number of Phase I and ii clinical trials have been initiated to test whether bispecific antibodies could redirect immune effecters against tumor cells in cancer patients. Recently, results from those trials showed beneficial effects in some patients but it is clear many problems remain to be solved. in addition, molecular engineering approaches are providing new and improved sources of clinically relevant bispecific antibodies.
Notes
Times Cited: 43 English Review 241BP CURR OPIN IMMUNOL